Setmelanotide: complete guide

Setmelanotide is an MC4 receptor agonist sold as Imcivree, and this guide covers its structure, labeled uses, trials, side effects and regulatory status as of November 17, 2026.

Complete guide6 min read

Key takeaway

Setmelanotide is an MC4 receptor agonist with the formula C49H68N18O9S2. FDA first approved Imcivree on November 25, 2020. The label now covers obesity from POMC, PCSK1 or LEPR deficiency, Bardet-Biedl syndrome and, since March 19, 2026, acquired hypothalamic obesity. It is not indicated for general obesity. In a phase 3 trial in hypothalamic obesity, BMI fell 16.5% with setmelanotide and rose 3.3% with placebo.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Imcivree is an FDA-approved prescription drug under NDA 213793.” (this article)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited4 in this article · 4 across 1 article on Setmelanotide
Related productsIncretin analogs

Setmelanotide is a small ring-shaped peptide that switches on the melanocortin-4 (MC4) receptor, a brain signal for hunger and fullness. Sold as Imcivree, it is FDA-approved for obesity with certain rare genetic or acquired causes. This guide covers its structure, action, label, trials and status. Every source was checked on November 17, 2026.

Quick answer: Setmelanotide is a prescription drug for a narrow group of people whose obesity comes from a broken MC4 signaling pathway. Its label excludes common, general obesity. It is not a GLP-1 drug. Skin darkening is among its most common label side effects.

Vitrapep does not sell setmelanotide; this page is a reference summary of published research and regulatory information. It is not medical advice.

What is setmelanotide?

Setmelanotide is a short peptide closed into a ring. The Imcivree label calls it “an 8 amino acid cyclic peptide analog of endogenous melanocortin peptide α-MSH” (Imcivree label, 2026). PubChem lists the formula C49H68N18O9S2 and a molecular weight of 1117.3 g/mol (PubChem CID 11993702). Its development codes include RM-493 and BIM-22493.

Rhythm Pharmaceuticals markets it as Imcivree. Drugs@FDA lists the original approval on November 25, 2020, as a new molecular entity (Drugs@FDA, NDA 213793).

Table 1

Setmelanotide: key facts

Fact Detail
Structure Cyclic peptide of 8 amino acids; analog of alpha-MSH
Class Melanocortin-4 (MC4) receptor agonist
Molecular formula C49H68N18O9S2
Molecular weight 1117.3 g/mol (PubChem)
First FDA approval November 25, 2020 (NDA 213793)
Brand names Imcivree (Rhythm Pharmaceuticals)

How does setmelanotide work?

The MC4 receptor sits in the brain. The label says it helps regulate hunger, satiety and energy expenditure. Some genetic and acquired conditions leave this pathway with too little natural signal.

The label describes setmelanotide as “an MC4 receptor agonist with 20-fold less activity at the melanocortin 3 (MC3)” and MC1 receptors. In people with too little MC4 activation, it may restore pathway activity. The label links this to lower food intake and higher energy expenditure.

Setmelanotide also acts on MC1 receptors in skin pigment cells. That raises melanin and darkens the skin, independent of ultraviolet light, the label says. This explains its most common side effect. Bremelanotide, covered in our PT-141 guide, is another melanocortin receptor drug. Our page on KPV and melanocortin signaling explains the receptor family.

What is setmelanotide approved for?

The current label was revised in April 2026. It states that Imcivree “is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients.” It names two groups:

  • Patients 4 years and older with acquired hypothalamic obesity.
  • Patients 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome, or to POMC, PCSK1 or LEPR deficiency. For the gene deficiencies, testing must show variants classed as pathogenic, likely pathogenic or of uncertain significance.

The label’s limitations of use matter as much. Imcivree is not indicated when those gene variants are benign or likely benign. It is also not indicated for other types of obesity, including other genetic syndromes and general (polygenic) obesity.

The indications arrived in steps. FDA’s 2020 announcement called Imcivree “the first FDA-approved treatment for these genetic conditions” (FDA, 2020). Bardet-Biedl syndrome followed in June 2022 (FDA, 2022). FDA’s March 19, 2026 letter added acquired hypothalamic obesity (FDA, 2026).

What did the key trials show?

All three trials below were in humans. Each enrolled people with a specific cause of obesity.

POMC and LEPR deficiency (2020). Two single-arm, open-label phase 3 trials enrolled people aged 6 and older (Clément et al., 2020; NCT02896192, NCT03287960). The primary endpoint was at least 10% weight loss at about one year. It was met by 8 of 10 participants with POMC deficiency (80%). It was met by 5 of 11 with LEPR deficiency (45%). There were no serious treatment-related adverse events.

Bardet-Biedl syndrome (2022). This phase 3 trial had a 14-week double-blind, placebo-controlled period, then 52 weeks of open-label treatment (Haqq et al., 2022; NCT03746522). It randomized 38 patients with Bardet-Biedl or Alström syndrome. Among Bardet-Biedl patients aged 12 and older, 32.3% lost at least 10% of body weight after 52 weeks (p=0.0006). Results in Alström syndrome were inconclusive.

Acquired hypothalamic obesity (2026). The TRANSCEND trial randomized 120 people aged 4 to 66 to setmelanotide or placebo (Miller et al., 2026; NCT05774756). All had a history of a hypothalamic tumor, lesion or injury. At 52 weeks, BMI changed by −16.5% with setmelanotide and +3.3% with placebo (P<0.001). Hunger scores also fell more with setmelanotide in participants aged 12 and older.

What side effects does the label list?

The Imcivree label has no boxed warning. It lists the most common adverse reactions, at 20% or more in at least one indication, as:

  • skin hyperpigmentation;
  • injection site reactions;
  • nausea, vomiting, diarrhea and abdominal pain;
  • headache and depression;
  • spontaneous penile erection.

Its warnings and precautions cover disturbance in sexual arousal, depression and suicidal ideation, and hypersensitivity reactions. They also cover skin hyperpigmentation, darkening of existing moles and new moles. Two warnings apply to acquired hypothalamic obesity: acute adrenal insufficiency, and sodium imbalance in patients who also have central diabetes insipidus.

Trial reports add context. In TRANSCEND, serious adverse events occurred in 28% of the setmelanotide group and 8% of the placebo group. In the Bardet-Biedl trial, 61% had skin hyperpigmentation. That trial’s serious events were not considered treatment-related.

What is setmelanotide’s regulatory status, and is it used in research?

Prescription drug. Imcivree is an FDA-approved prescription drug under NDA 213793. Drugs@FDA lists three later approvals for new indications, in 2022, 2024 and 2026.

Sport. WADA’s 2026 Prohibited List does not name setmelanotide. Athletes should check with their anti-doping organization. See our guide to peptides on the 2026 WADA list.

Research. Setmelanotide is a research tool for studying the MC4 pathway. In diet-induced obese rhesus macaques, it was tested under the code BIM-22493 (Kievit et al., 2013). Food intake fell briefly by 35%, and body weight fell 13.5% over 8 weeks. Unlike another MC4 agonist, it did not raise blood pressure or heart rate. These are animal data. For labeling terms used with laboratory peptides, see what research use only means.

Afamelanotide, a related drug that acts mainly on skin MC1 receptors, is covered in our afamelanotide guide. For the wider family, see peptide hormones and how peptides work.

Frequently asked questions about setmelanotide

Is setmelanotide approved for general obesity?

No. The label states it is not indicated for general (polygenic) obesity or for obesity types outside its listed conditions.

Is setmelanotide a GLP-1 drug?

No. The label describes it as an MC4 receptor agonist. It acts on the melanocortin pathway, not the GLP-1 receptor.

Why does setmelanotide darken the skin?

It also activates MC1 receptors on pigment cells. The label says this raises melanin, independent of ultraviolet light.

When was hypothalamic obesity added to the label?

FDA approved the acquired hypothalamic obesity indication on March 19, 2026, for patients aged 4 and older.

Is setmelanotide banned by WADA?

The 2026 list does not name it. Athletes should confirm with their anti-doping organization.

What to know now

  • What it is: an 8-amino-acid cyclic peptide that activates the MC4 receptor.
  • Approval: Imcivree, first approved November 25, 2020.
  • Labeled uses: obesity from POMC, PCSK1 or LEPR deficiency, Bardet-Biedl syndrome, and acquired hypothalamic obesity.
  • Not for: general obesity or benign gene variants.
  • Key trial: TRANSCEND found a 16.5% BMI fall versus a 3.3% rise with placebo.
  • Side effects: skin darkening, injection site reactions, nausea and others; no boxed warning.

What we’re watching

TRANSCEND, which ClinicalTrials.gov lists as active, not recruiting. Further Imcivree label changes on DailyMed and Drugs@FDA. And WADA’s 2027 Prohibited List, which takes effect on January 1, 2027.

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: Rhythm Pharmaceuticals 2026, IMCIVREE (setmelanotide) prescribing information; U.S. Food and Drug Administration. (n.d.). Drugs@FDA: NDA 213793, Drugs@FDA: NDA 213793, IMCIVREE; National Center for Biotechnology Information. (n.d.). PubChem compound summary for CID 11993702, PubChem compound summary for CID 11993702, setmelanotide; U.S. Food and Drug Administration 2020; U.S. Food and Drug Administration 2022; U.S. Food and Drug Administration 2026, Supplement approval letter: NDA 213793/S-009, Imcivree (setmelanotide); Clément 2020, The Lancet Diabetes & Endocrinology, 8; Haqq 2022, The Lancet Diabetes & Endocrinology, 10; Miller 2026, New England Journal of Medicine, 395; Rhythm Pharmaceuticals, A trial of setmelanotide in acquired hypothalamic obesity; Kievit 2013, Diabetes, 62; World Anti-Doping Agency 2025, World Anti-Doping Code International Standard: Prohibited List 2026. All 12 citations

Back to the research library

References

  1. Rhythm Pharmaceuticals, Inc. (2026). IMCIVREE (setmelanotide) prescribing information (revised April 2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70c3ccf7-4df0-4c75-ba07-fede9970c8d9
  2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: NDA 213793, IMCIVREE. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213793
  3. National Center for Biotechnology Information. (n.d.). PubChem compound summary for CID 11993702, setmelanotide. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/11993702
  4. U.S. Food and Drug Administration. (2020, November 27). FDA approves first treatment for weight management for people with certain rare genetic conditions. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-weight-management-people-certain-rare-genetic-conditions
  5. U.S. Food and Drug Administration. (2022, June 16). FDA approves treatment for weight management in patients with Bardet-Biedl syndrome aged 6 or older. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-weight-management-patients-bardet-biedl-syndrome-aged-6-or-older
  6. U.S. Food and Drug Administration. (2026, March 19). Supplement approval letter: NDA 213793/S-009, Imcivree (setmelanotide). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/213793Orig1s009ltr.pdf
  7. Clément, K., van den Akker, E., Argente, J., et al. (2020). Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: Single-arm, open-label, multicentre, phase 3 trials. The Lancet Diabetes & Endocrinology, 8(12), 960–970. PMID 33137293. https://doi.org/10.1016/S2213-8587(20)30364-8
  8. Haqq, A. M., Chung, W. K., Dollfus, H., et al. (2022). Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. The Lancet Diabetes & Endocrinology, 10(12), 859–868. PMID 36356613. https://doi.org/10.1016/S2213-8587(22)00277-7
  9. Miller, J. L., van Santen, H. M., Phillips, S. A., et al. (2026). Setmelanotide for the treatment of acquired hypothalamic obesity. New England Journal of Medicine, 395(2), 138–150. PMID 42418774. https://doi.org/10.1056/NEJMoa2512275
  10. Rhythm Pharmaceuticals, Inc. (n.d.). A trial of setmelanotide in acquired hypothalamic obesity (ClinicalTrials.gov ID NCT05774756). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT05774756
  11. Kievit, P., Halem, H., Marks, D. L., et al. (2013). Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes, 62(2), 490–497. PMID 23048186. https://doi.org/10.2337/db12-0598
  12. World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026 (in effect January 1, 2026). https://www.wada-ama.org/en/prohibited-list